RxDoctor Payments Data

Nicole Labor

Addiction Medicine · Akron, OHNPI 1598908485

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,887 of the $17,167 with a category attached, or 75.1%. Indivior Inc. accounts for 87.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $15,985, more than ten times the $150 reported in 2019. Among addiction medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,167in general payments, 2019–2025

Across 146 payments — averaging $117.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$15K
  • Braeburn Inc.$880
  • Orexo US, Inc.$360
  • Alkermes, Inc.$223
  • Revance Therapeutics, Inc.$199
  • Merz North America, Inc.$129
  • plus $413 from 9 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Speaking & faculty fees$12,88775%
  • Travel & lodging$1,1417%
  • Food & beverage$3,13718%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,167 in reported general payments places this provider in the 95th percentile of 98 addiction medicine providers in Ohio.

See all addiction medicine providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrixadiBuprenorphine16$24,825
VivitrolNaltrexone Microspheres12$20,291
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl80$12,768
ZubsolvBuprenorphine Hcl/Naloxone Hcl28$11,776
MresviaRsv Vaccine, Pref, Mrna/Pf33$10,560
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$8,699
AbrysvoRsv Vacc, Pref A And Pref B/Pf20$6,498
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,458
Ibuprofen20$304
Gabapentin11$303
Atorvastatin Calcium14$265
Lisinopril20$258
Amlodipine Besylate14$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braeburn Inc.Brixadi$880$24,82516 claims
Alkermes, Inc.Vivitrol$223$20,29112 claims
Orexo US, Inc.Zubsolv$360$11,77628 claims
Indivior Inc.Suboxone$14,962$8,69911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 addiction medicine providers in Ohio.

Other addiction medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →